Warmly Congratulate Keyuan Pharmaceutical Co. LTD. Listing on Shenzhen Stock Exchange GEM!
On April 4, 2023, Shandong Keyuan Pharmaceutical Co., LTD. (hereinafter referred to as "Keyuan Pharma") was listed on the Shenzhen Stock Exchange, Stock abbreviation: Keyuan Pharma, Stock code: 301281, the sponsor is China Securities Co., LTD.
Keyuan Pharma is mainly engaged in the research and development, production and sales of chemical APIs and FDF. Since its establishment, Keyuan Pharma has always focused on the research and development and manufacturing of chemical APIs, and has expanded some chemical FDF business based on characteristic APIs, and is committed to becoming a leading domestic and internationally competitive chemical API manufacturing enterprise.
Wang Hongzhi, Standing Committee Member and Vice Mayor of Jinan City; Yuan Changkui, Party Secretary of Shanghe County; Feng Yi, Director of Jinan Local Financial Regulatory Bureau; Liu Lianjie, member of Investment Banking Management Committee of China Securities Co., LTD.; Zhang Hua, President of Qilu Bank Co., LTD.; Pang Xianhui, General manager of Strategic Customer Department and Deputy President of Jinan Branch of China Construction Bank; Gao Yuankun, chairman and President of Linuo Group, Lun Lijun, chairman of Keyuan Pharma.and representatives of customers, partners, company management team and intermediaries participated in the listing ceremony..
At 9:25, Wang Hongzhi, Standing Committee Member and Vice Mayor of Jinan City; Yuan Changkui, Party Secretary of Shanghe County, Gao Yuankun, chairman and president of Lino Group, and Lun Lijun, chairman of Keyuan Pharma, opened the market with a gong. Keyuan Pharma issued shares for the first time and was officially listed on the GEM.
Feng Yi, director of Jinan Local Financial Regulatory Bureau, said at the listing ceremony that Keyuan Pharma, as the representative of Jinan excellent private enterprises, is the second listed enterprise in our city this year. We will continue to create a more superior environment for Keyuan Pharma, provide more accurate services, and fully support the innovation and development of enterprise. He also hoped that Keyuan Pharma will take the listing as a new starting point, continuously improve the internal governance level of the enterprise, comply with the laws and regulations of the capital market, further enhance the comprehensive competitiveness, return the majority of investors with a good corporate image, excellent business performance, and rich market dividends, and make greater contributions to the high-quality development of Jinan biomedicine and health industry.
Mr. Lun Lijun, chairman of Keyuan Pharma, said that the listing is a major breakthrough in the development process of Keyuan Pharmal, we will firmly grasp the development opportunity, with the strong wind of market, constantly increase the investment in scientific and technological research and development, continue to expand the market size, and strive to return the society and the majority of investors.
The global pharmaceutical market is growing steadily; The advantages of manufacturing is significant.
The steady development of the world economy, the continuous growth of the total population and the continuous increase of the aging degree of the population, and the continuous improvement of people's income and health awareness, the global demand for drugs is on the rise, which has led to the sustained and rapid growth of the pharmaceutical market. According to the consulting firm Frost & Sullivan analysis data, the total global pharmaceutical market in 2019 was $1324.5 billion, and it is expected to reach $1639.5 billion by 2024, with a compound annual growth rate of 4.6%, and the growth is relatively stable.
After nearly 20 years of chemical synthesis production experience accumulation and innovation of technology research and development, Keyuan Pharma has a strong production capacity of chemical raw materials, complete synthesis equipment, mature synthesis process, strong industrialization capacity and quality control standards, and constantly improve reaction yield or product purity, improve production efficiency, reduce three wastes emission. The stability and safety of the production process have also been consolidated, and the core technology applied to the production of chemical APIs has been gradually accumulated. Among them, the single-step reaction yield of preparation of Crude Gliclazide is more than 90%, the utilization rate of raw materials is high, the cost is low, the total waste is reduced by 20%, and the purity of the product is more than 99.8%. The condensation yield of Metformin Hydrochloride is more than 90%, and the impurity content is less than 0.05%. The purity of Ropivacaine Hydrochloride is over 99.8% and the quality is stable.
Continue to increase investment for research and development; Continue to optimize the production process
Keyuan Pharma adopts the combination of independent research and development and outsourcing development for product research and development. In terms of independent research and development, the company takes the technology management center as the core, unified management of the company's research and development work, and the implementation of the company's research and development strategy. The R&D institute consists of the technology department and the Quality Research Department. In terms of outsourcing development, the company cooperates with well-known R&D institutions such as Sunshine Nohe to jointly promote the development progress of products. In addition, Keyuan Pharma continues to strengthen the product layout in key treatment areas such as hypoglycemia, anesthesia, cardiovascular, and psychiatry, while expanding the fields of digestive, hemostatic, pain relief, anti-inflammatory and other diseases. Relying on advanced research and development technology innovation platforms, through precise and controllable process research and development, high standard quality analysis and professional domestic and international registration certification, adhere to market orientation and clinical effect orientation, and constantly introduce new chemical APIs for the company to inject new vitality into the future development of the company.
It is reported that Keyuan Pharma's leading products such as Gliclazide, Metformin Hydrochloride, Ropivacaine Hydrochloride, Isosorbide Mononitrate and other drug substances have a long production and operation history, with certain scale and economic advantages, is a leading enterprise in segmented product categories and have achieved relatively stable revenue and profits. At the same time, the company continues to strengthen investment of research and development, the introduction of automated production lines, strengthen the continuous optimization and development of the existing leading product production process, in order to achieve the improvement of production efficiency and the reduction of production costs, will further strengthen the advantages of economies of scale.
"API + FDF" integrated development strategy; Operating income increased steadily
Based on the strong manufacturing advantages of APIs, Keyuan Pharma continuously strengthens the development of new products, expands the scope of product development and production, and extends the value chain of product production. At present, it has formed a product pattern of multiple categories of drugs such as hypoglycemic, anesthetic, cardiovascular and psychiatric drugs. With Gliclazide, Metformin Hydrochloride, Ropivacaine Hydrochloride, Isosorbide Mononitrate and other mature APIs as the leading products, the company achieved relatively stable revenue and profit. At the same time, Keyuan Pharma also continues to expand the scope of product research and development and production, through the acquisition of Linuo Pharmaceutical under the same group, and actively develop the integrated development strategy of "API + FDF", adding new impetus and highlights to the growth of future performance.
The funds raised by Keyuan Pharma will be used for the technical transformation project of the integrated production line of APIs, the green intelligent flexible production line project of pharmaceutical raw materials, the construction of the R&D institute, the drug research and development project and the supplementary working capital.
In the future, Keyuan Pharma will take this A-share listing as a new development opportunity, combined with this raised capital investment project, improve the production process of main products, enrich product categories, continue to introduce R&D talents to enhance R&D capabilities, and further optimize the company's business layout. At the same time, Keyuan Pharma will continue to strengthen research and development and innovation capabilities, consolidate the market position of existing product lines, deepen the channel network layout, continue to enhance the company's product market share and international influence, and strive to become a leading domestic chemical API and FDF enterprises.